Edition:
United Kingdom

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,052.00DKK
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
kr.1,052.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
279,582
52-wk High
kr.1,489.00
52-wk Low
kr.1,052.00

Latest Key Developments (Source: Significant Developments)

Biotech Genmab sees 2018 expense growth of 40-50 pct
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - FOLLOWING ARE STATEMENTS FROM GENMAB'S R'N'D UPDATE IN ATLANTA, GEORGIA: :DENMARK'S GENMAB SEES 2018 EXPENSE GROWTH OF 40-50 PERCENT DRIVEN BY PIPELINE INVESTMENTS.SAYS ROYALTY FUNDS 100 PCT OF EXPENSE INVESTMENT.GENMAB TO CONDUCT NEW AND LARGER TISOTUMAB VEDOTIN TRIALS IN 2018.SAYS 6 PRE-CLINICAL PRODUCTS RAPIDLY ADVANCING.SAYS 2018 WILL BE 6TH YEAR OF PROFITABILITY.  Full Article

Genmab Achieves $20 Million Milestone In Daratumumab Collaboration With Janssen
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Genmab A/S ::GENMAB ACHIEVES USD 20 MILLION MILESTONE IN DARATUMUMAB COLLABORATION WITH JANSSEN AND UPDATES FINANCIAL GUIDANCE.GENMAB - EXPECT 2017 REVENUE TO BE IN RANGE OF DKK 2,240 - 2,440 MILLION.GENMAB - PAYMENT RELATES TO PHASE III ANDROMEDA STUDY OF DARATUMUMAB IN COMBINATION WITH CYCLOPHOSPHAMIDE, BORTEZOMIB & DEXAMETHASONE IN AMYLOIDOSIS.  Full Article

Genmab: $50 mln milestone payment in collaboration on Darzalex
Friday, 17 Nov 2017 

Nov 17(Reuters) - GENMAB A/S : :SAID ON FRIDAY WILL RECEIVE MILESTONE PAYMENT OF USD 50 MILLION IN DARZALEX COLLABORATION WITH JANSSEN BIOTECH, INC..SAID MILESTONE TRIGGERED BY SALES OF DARZALEX REACHING USD 1 BILLION IN A CALENDAR YEAR.THE MILESTONE WAS INCLUDED IN GENMAB’S 2017 FINANCIAL GUIDANCE PUBLISHED ON NOVEMBER 14, 2017.  Full Article

‍Genmab says expect 2017 revenue to be in range of DKK 2,110 – 2,310 mln
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Genmab ::‍GENMAB ACHIEVES USD 25 MILLION MILESTONE FOR FIRST COMMERCIAL SALE OF DARZALEX® (DARATUMUMAB) IN JAPAN AND UPDATES FINANCIAL GUIDANCE​.GENMAB SAYS ‍EXPECT 2017 REVENUE TO BE IN RANGE OF DKK 2.110 - 2.310 MILLION​.GENMAB-EXPECT DARZALEX ROYALTIES TO REMAIN IN RANGE OF DKK 930 - 1,100 MILLION WHICH ARE BASED ON ESTIMATED USD 1,100 - 1,300 MILLION OF DARZALEX SALES IN 2017​.‍NOW EXPECT OPERATING INCOME FOR 2017 TO BE APPROXIMATELY DKK 1,060 - 1,260 MILLION, COMPARED TO DKK 900 - 1,100 MILLION IN PREVIOUS GUIDANCE​.  Full Article

Genmab Q3 net loss DKK 5.7 mln, misses estimates
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - GENMAB A/S ::GENMAB ANNOUNCES FINANCIAL RESULTS FOR THE FIRST NINE MONTHS OF 2017 <<>>.‍REVENUE WAS DKK 1,348 MILLION IN FIRST NINE MONTHS OF 2017 COMPARED TO DKK 889 MILLION IN FIRST NINE MONTHS OF 2016​.‍OPERATING INCOME WAS DKK 641 MILLION IN FIRST NINE MONTHS OF 2017 COMPARED TO DKK 345 MILLION IN FIRST NINE MONTHS OF 2016​.‍IS MAINTAINING ITS 2017 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 22, 2017 AND REITERATED ON SEPTEMBER 27, 2017​.Q3 REVENUE DKK ‍​ 323.4 MILLION (REUTERS POLL DKK 333 MILLION).Q3 OPERATING RESULT DKK ‍​ 58.3 MILLION (REUTERS POLL DKK 59 MILLION).Q3 NET LOSS DKK ‍​5.7 MILLION (REUTERS POLL PROFIT DKK 67.3 MILLION).  Full Article

Genmab: ‍worldwide net sales of darzalex $317 mln in Q3
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - GENMAB A/S :GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR THIRD QUARTER OF 2017.‍WORLDWIDE NET SALES OF DARZALEX (DARATUMUMAB) AS REPORTED BY JOHNSON & JOHNSON WERE USD 317 MILLION IN Q3 OF 2017​.‍GENMAB WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC.​.  Full Article

Genmab and Seattle Genetics to start Phase II study of tisotumab vedotin
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Genmab A/S :Genmab and Seattle Genetics to initiate new study of novel antibody-drug conjugate tisotumab vedotin in cervical cancer.Genmab - ‍companies plan to start enrolling patients by first half of 2018​.Genmab - ‍co, Seattle Genetics to start phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer​.  Full Article

Genmab says U.S. FDA grants priority review for daratumumab in relapsed multiple myeloma
Friday, 7 Oct 2016 

Genmab : u.s. Fda grants priority review for daratumumab in relapsed multiple myeloma . Sbla was submitted by genmab's licensing partner, janssen biotech, inc. In august 2016 . Pdufa date set at june 17, 2017 . Fda has assigned pdufa target date of february 17, 2017 to take a decision on daratumumab . Fda has assigned a prescription drug user fee act (pdufa) target date of february 17, 2017 . Sbla submission also included data from phase i study of daratumumab in combination with pomalidomide and dexamethasone .Pdufa date for combination of daratumumab with pomalidomide/dexamethasone is june 17, 2017.  Full Article

Genmab: FDA approves Arzerra for treatment of relapsed chronic lymphocytic leukemia
Wednesday, 31 Aug 2016 

Genmab A/S :FDA approved a supplemental biologics license application for use of ofatumumab ((Arzerra) in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia.  Full Article

Genmab: European Regulatory submission for Daratumumab in Relapsed Multiple Myeloma
Tuesday, 23 Aug 2016 

Genmab A/S : Janssen Pharmaceutica NV has submitted a variation to the Marketing Authorization to the European Medicines Agency (EMA) seeking to broaden the existing marketing authorization for daratumumab (DARZALEX) to include treatment of adult patients with multiple myeloma who have received at least one prior therapy . The submission of the application triggers milestone payments totaling $10 million to Genmab from Janssen .In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab.  Full Article

UPDATE 4-France's Sanofi pins hopes on new drugs after setbacks

* CEO says company on track to sell European generics unit (Adds CEO comments, details, updates shares)